Like buying Apple in 1997,buy Organovo today .....

hat sich erledigt, das scheint wohl arcam ab zu sein und nicht organovo, die frage ist, schiesst die aktie nach einer übernahme überhaupt hoch?

 

SAN DIEGO, July 9, 2013 /PRNewswire/ --  Organovo Holdings, Inc. (ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, is pleased to announce that its common shares have been approved to list on the NYSE MKT and will begin trading on the New York Stock Exchange on July 11, 2013.  The Company will continue to trade under the symbol "ONVO" but will withdraw its shares from listing on the OTC QX concurrent with listing its shares on the NYSE MKT, the premier US equities market for listing and trading of small growth companies.

"Trading on the New York Stock Exchange is an important milestone for Organovo and will be valuable to our business and shareholders. Our decision to move to the NYSE MKT was based on a firm belief that the exchange offers the best set of conditions for Organovo's success, and thus the best opportunity to add value for our shareholders," said Keith Murphy, President and CEO of Organovo Holdings, Inc..  "We found NYSE to have made an unparalleled commitment to providing a fertile platform for growth to early stage biotechnology companies, and we look forward to a great future on the exchange."

MFG
Chali  

Organovo Holdings (NYSEMKT: ONVO  ) was one of last week's biggest winners, soaring 55% after making the leap to the more prolific NYSE MKT exchange.

A bigger stage plays well when you have a neat tale to tell, and Organovo certainly has all of the makings of a hot story stock.

Organovo takes 3-D printing to a seemingly implausible extreme. Its bioprinting process can generate a reasonable proxy to human tissue in a lab that can be used in culture plates or bioreactors for medical research and therapeutic applications.

Yes, that's pretty cool, and recent investors seeing the stock jump from $3.87 to $6.01 in a single week have a good reason to get giddy.

Unfortunately, long-term investors have seen this before.

The stock traded as low as $2.35 in May of last year, only to peak at $10.90 a month later and bottom out at $1.49 the month after that.

Organovo is a volatile little specimen, and it can thank 3D Systems (NYSE: DDD  ) and Stratasys (NASDAQ: SSYS  ) for all of the attention.

3-D printing wasn't on the investing radar until last year when 3D Systems and Stratasys made it fashionable. Manufacturing printers capable of cranking out on-demand aircraft parts, prosthetics, orthodontics, and even your nephew's missing Lego piece is no longer the handiwork of science fiction. Sure, the printers are slow as molasses and pretty darn expensive, but we've seen technology get faster and cheaper over time.

Office supply chains are starting to stock 3-D printers. The mainstream push is coming.

Stratasys shares soared 164% last year, and they come off as slackers compared to the 284% pop for 3D Systems.

Their Wall Street success has spawned interest in other companies with 3-D printing models, though clearly there's a major difference between the reality that 3D Systems and Stratasys have achieved and the unfulfilled yet lofty ambitions of Organovo.

For now, the wild swings are fueled by speculation. Organovo isn't generating any kind of meaningful revenue. It cranked out a mere $0.2 million in revenue during the first three months of this year, and half of that was the result of grant revenue.

There will be more rallies like we experienced last week, and it wouldn't be a surprise to see the company try to shore up its balance sheet by raising new financing during the good times. There will also be more crashes like we had last summer, and the "I told you so" will sting until the story stock regains its swagger. Until the market gets a clear snapshot on the viability of Organovo's business and its legitimate upside and market positioning, speculators on both ends will concoct their own theories for why the stock will either change the world or fade away.

Keep an eye on Organovo, but always be aware that this tantalizing Petri dish of an investment is going to be ridiculously risky in the near term.

 

Period Ending Dec 30, 2012 Sep 29, 2012 Jun 29, 2012 Mar 30, 2012
Total Revenue  349    469    259    120    
Cost of Revenue -   -   -   -  

Gross Profit  349    469    259    120    

Operating Expenses
Research Development 1,131   1,105   653   547  
Selling General and Administrative 2,141   2,981   1,056   902  
Non Recurring -   -   -   -  
Others -   -   -   -  
 
Total Operating Expenses -   -   -   -  


Operating Income or Loss  (2,922)  (3,618)  (1,450)  (1,329)  

Income from Continuing Operations
Total Other Income/Expenses Net (6,642) 42,096   (33,935) (32,534)
Earnings Before Interest And Taxes (9,565) 38,478   (35,385) (33,863)
Interest Expense 0   0   -   3,218  
Income Before Tax (9,565) 38,478   (35,385) (37,081)
Income Tax Expense -   -   -   -  
Minority Interest -   -   -   -  
 
Net Income From Continuing Ops (9,565) 38,478   (35,385) (37,081)

Non-recurring Events
Discontinued Operations -   -   -   -  
Extraordinary Items -   -   -   -  
Effect Of Accounting Changes -   -   -   -  
Other Items -   -   -   -  


Net Income  (9,565)  38,478    (35,385)  (37,081)  
Preferred Stock And Other Adjustments -   -   -   -  

Net Income Applicable To Common Shares  (9,565)  38,478    (35,385)  (37,081
 

kennt ja nur eine Richtung, bin jetzt auch dabei... In Zukunft menschliche Zellen mit 3D Druckern herzustellen ist kaum vorstellbar.

 

 

verdoppelt?!

Was geht mit Organovo ab?

Überlege mir zu verkaufen...

 

Entwicklung von Organovo hat am 10.7.2013 eingesetzt.Sie beruht m.M. darauf ,dass Organovo kein OTC Wert mehr ist und seit dem 11.7.2013 regulär und reguliert an der Nasdaq gehandelt wird.

 

Alternative - Wake Forest Institute for Regenerative Medicine :

3D-Drucker macht menschliche Organe in Minigröße
Nachrichtenquelle: Pressetext (News)  |  18.09.2013, 06:00  |  60 Aufrufe  |  0   |   druckversion


Winston-Salem (pte001/18.09.2013/06:00) - Menschliche Organe in Miniaturgröße haben Forscher des Wake Forest Institute for Regenerative Medicine http://wakehealth.edu/WFIRM mit einem modifizierten 3D-Drucker hergestellt. Sie werden jetzt für Tests an neuen Impfstoffen eingesetzt. Im Rahmen dieses Projekts werden menschliche Zellen repliziert, die die Funktionen von Organen wie Herz, Leber, Lunge oder Blutgefäßen nachahmen. Diese Organe werden dann auf einem Mikrochip platziert und mit einem Blutersatz verbunden. Damit wird es möglich, Behandlungsmöglichkeiten zu überprüfen.
Google Anzeigen
Diese Aktien kaufen
Dieser Mann hat nach nur 42 Wochen Ihr Geld ver-10-facht
Uebernahme-Sensor.de


Militärischer und ziviler Einsatz

Das U.S. Department of Defense http://defense.gov hat die neue Technologie mit 24 Mio. Dollar unterstützt. Bioprinting, eine Art des 3D-Drucks, bei der menschliches Gewebe hergestellt wird, ist an sich kein neues Verfahren. Auch die Idee, menschliches Gewebe in 3D auf einem Mikrochip zu züchten, ist kein Novum. Bei den aktuellen Tests werden jedoch erstmals verschiedene Organe im gleichen Gerät miteinander kombiniert. Damit wird die menschliche Reaktion auf chemische Giftstoffe oder biologische Wirkstoffe modellhaft sichtbar.

Die von den Wissenschaftlern entwickelten modifizierten 3D-Drucker drucken menschliche Zellen auf Hydrogel basierende Gerüste. Die im Labor hergestellten Organe werden in einem nächsten Schritt auf einem fünf Zentimeter großen Chip platziert und miteinander verbunden. Der verwendete Blutersatz ähnelt jenem, der auch bei der chirurgischen Behandlung von Traumata eingesetzt wird. Der Blutersatz hält die Zellen am Leben und kann auch eingesetzt werden, um chemische oder biologische Substanzen oder auch Medikamente in das System einzubringen. Sensoren messen die Temperatur in Echtzeit, überprüfen die Sauerstoffwerte, den pH-Wert und andere Faktoren.

Alternative zu Tierversuchen

Der leitende Wissenschaftler Anthony Atala betont, dass dieses Verfahren eingesetzt werden kann, um die Auswirkungen von chemischen und biologischen Substanzen vorherzusagen, aber auch um die Wirksamkeit neuer Behandlungsansätze zu überprüfen. "Die Tests finden an echtem menschlichen Gewebe statt. Das funktioniert deutlich besser als Tierversuche." Die Finanzierung des Projektes wurde durch die Defense Threat Reduction Agency http://dtra.mil ermöglicht, eine Abteilung der US Regierung, die für die Bekämpfung nuklearer, chemischer und biologischer Waffen zuständig ist.

Die durchgeführten Tests sollen die Kosten und die Zeit deutlich reduzieren, die notwendig ist, um medizinische Gegenmaßnahmen gegen Angriffe von Bioterroristen abzuwehren. Laut den Wissenschaftlern des Wake Forest Institute for Regenerative Medicine besteht die Möglichkeit auf Gegenmittel zum Beispiel gegen Sarin zu testen, das vor kurzem in Syrien gegen Zivilisten eingesetzt wurde. Laut Atala, der auf regenerative Medizin spezialisiert ist, wurde das Bioprinting von den Wissenschaftlern zuerst für die Herstellung von Gewebe und Organen für Patienten eingesetzt.

Originalgröße schon bald möglich

Atalas Team ist es gelungen, flache Organe wie Haut oder röhrenförmige Organe wie Blutgefäße und sogar hohe, nicht röhrenförmige Organe wie die Blase oder den Magen zu produzieren, die über ein komplexere Strukturen und Funktionen verfügen. Die Herstellung von Organen wie dem Herzen oder der Leber gehört derzeit jedoch noch zu den größten Herausforderungen. Eine Kombination von einem Mikroskop und einem Inkubator wird für die Herstellung der Organe eingesetzt.

Es dauert rund 30 Minuten, um eine Niere oder ein Herz im Miniaturformat zu produzieren. Die Größe entspricht dann in etwa der eines kleinen Keks. Atala erklärt, dass auf einen Zentimeter so viele Zellen kommen, dass ein großes Organ eine sehr komplexe Herausforderung darstellt. Die Herstellung von Organen in Originalgröße dürfte jedoch in nicht allzu ferner Zukunft möglich sein. Die Wissenschaftler arbeiten derzeit an Organen, die als Implantate eingesetzt werden können.

(Ende)

Aussender: pressetext.redaktion Ansprechpartner: Michaela Monschein Tel.: +43-1-81140-300 E-Mail: monschein@pressetext.com Website: www.pressetext.com

[ Quelle: http://www.pressetext.com/news/20130918001 ]
Themen: Syrien, Finanzierung, Waffen
 

http://www.so-sieht-unsere-zukunft-aus.de/3d-drucker-verandern-alles/  

To Invest

13 StepsFind a BrokerInvesting WikiPersonal Finance
Investing Commentary

BasicsETFsOptionsSmall-CapDividends & IncomeHigh GrowthValueMutual FundsInternational
CAPS Community

CAPS HomeCAPS HomeMy CAPSStocksScreenerPlayersBlogsTop TensTagsContestsContact UsHelp
Retirement

13 Retirement StepsIRAs401(k)s, Etc.Asset Allocation
Boards

Best OfFavorites & RepliesCustomizeStart a New Board
Fool Store
Organovo (NYSEMKT: ONVO  ) is a little company with a big dream: to use 3-D printing technology to create functional human organs. But that dream is far, far off into the future.

In order to reach that dream, the company has focused on more practical -- and realistic -- applications for its technology. The revenue created by these applications, the thinking goes, will help Organovo bridge the gap between now and the day when it might be able to realize the potential of printing organs.

While there's one industry that should soon account for most of Organovo's revenue, an interesting development earlier this month reveals that there might be more applications for the company's technology than originally thought.

Pharmaceuticals: The industry in the crosshairs
There's no industry that Organovo is more interested in focusing on right now than pharmaceuticals. As it stands, industry experts predict that almost 40% of the $50 billion spend annually by the pharmaceutical industry is on drugs that will eventually be ditched because of the toxicity that arises during human trials.

That's where Organovo's ability to print 3-D cells that mimic native human behavior comes in. Because these cells more closely resemble the behavior that occurs within the organs of the human body than standard 2-D cells, they are far more predictive of toxicities.

That's important because if pharmaceutical companies can catch toxicities earlier on, they can choose to either tweak their treatments or abandon them altogether. No matter the direction, the pharmaceutical companies end up saving a lot of money by catching these problems early in the process.

Already, Organovo has had working agreements in place with Pfizer (NYSE: PFE  ) and United Therapeutics (NASDAQ: UTHR  ) . The deal with Pfizer expired in 2012, and Organovo is waiting to hear back on whether Pfizer will pursue further collaborations. United Therapeutics, on the other hand, expanded the scope of its collaboration with Organovo last year, and research is still ongoing.

Organovo also disclosed in September that it had entered into an agreement with Roche (NASDAQOTH: RHHBY  ) , "exploring the use of 3D liver tissue in toxicology."

Just as importantly, Organovo plans to be able to deliver functional liver tissues for use by pharmaceutical companies in 2014 -- representing the first regular, recurring revenue stream the company plans to realize.

A surprising development
But while investors would be wise to keep most of their attention on developments within the pharmaceutical industry, Organovo also disclosed recently that at least one company outside of big pharma is also interested in 3-D bioprinting: L'Oreal (NASDAQOTH: LRLCY  ) .

Specific details of the agreement were not released, and L'Oreal does have some business interests within the pharmaceutical industry, but the release stated that L'Oreal would be "exploring the use of 3D skin for testing skin care products."

L'Oreal represents the world's largest cosmetic and beauty company, with more than $30 billion in sales in 2012. Any agreement with such a large player could open yet another revenue stream for Organovo -- which is a huge deal considering that Organovo has only generated $3.2 million in revenue since inception in 2007

MFG
Chali  

Earlier today, Organovo Holdings provided a summary of the data presented at the 3rd Annual Cell Therapy Bioprocessing Conference in Bethesda, MD International Bioprocessing Conference on October 22. The demonstration of extended function in Organovo's 3D liver tissues was achieved faster than Organovo's projected timeline of achieving these results by the end of 2013 and highlights progress in the development of a 3D Human Liver product, which is on track for launch in 2014. The company believes that a multi-cellular bioprinted 3D Liver system with extended life span in culture can provide superior results to current human cellular models and offer significant value to pharmaceutical researchers by enabling assessment of both biochemical and tissue responses. Shares of Organovo are up over 7% to $6.69 in midday trading  

"If further evidence that the technology is no passing fad were needed, a new report by Transparency Market Research predicts that the medical 3D printing market will grow in value from $354m last year to $965m in 2019, as good an indication as any that healthcare investment into 3D printing is comfortably being sustained and expanded."

Quelle: http://www.pharmaceutical-technology.com/features/...tion-technology/  

Hallo,

eine Frage an euch, denkt ihr jetzt wäre noch ein guter Zeitpunkt zum Einstieg in die Aktie?
Gibt es sonst irgendwelche Neuigkeiten zu Organovo?

Der Artikel hier ist vllt noch lesenswert.

http://www.fool.com/investing/general/2013/10/24/...-d-bioprinti.aspx  

http://seekingalpha.com/article/...email_the_daily_dispatch&ifp=0
 

... Frage schlechthin. Immerhin ist da schon einiges passiert im Kurs. Und die Artikel fabulieren alle wild in eine bunte Zukunft.Was dann tatsächlich gehen wird, muss man erst mal sehen.  

jau,das mit ARIA ging wohl nach hinten los,sorry,ich hab ARIA komplett geschmissen und bin bei CRME all in gegangen,ausserdem hab ich mir heute eine einstiegsposi in CETV gegönnt ......

MFG
Chali  

also,im moment auf jeden Fall und keiner weiss,wann der Hype zu Ende ist und alles in sich zusammenfällt,darauf warte ich ja ! Wer gerade einen völlig ungehypten Biotechbereich sucht und günstigst auf tiefstkurs einsteigen will,so wie ich es gemacht hab,der sollte hier gut aufgehoben sein:

http://www.ariva.de/forum/Thermogenesis-436467  

Organovo + Lab-Grown Meat = Return of the Dollar Menu?
By Maxx Chatsko | More Articles | Save For Later
October 27, 2013 | Comments (4)

The Dollar Menu will soon just be a memory. Image source: McDonald's.

I've become a bit of a health nut over the past year, but even I enjoy the occasional splurge at McDonald's (NYSE: MCD  ) . My favorite menu option? The McChicken from the Dollar Menu. The best news for the fitness-guru voices in my head? The Dollar Menu will be phased out of existence by November. It's a wonder that the food chain was able to keep soaring meat prices at bay for this long, but reality has finally caught up. Simply put, it's not economical to sell hamburgers for $1.  

Take a step back and you'll realize that the current state-of-the-art technology for meat production is actually pretty archaic. It's inefficient, expensive, and resource-hogging, and it nets a horrible return on the energy invested. I'm not advocating that everyone go vegan or vegetarian -- quite the opposite, actually. What if the technology existed to produce meat from the same cells found in cows, poultry, and pigs in a large-scale biomanufacturing facility? This innovative solution will be available in our lifetimes, thanks to 3-D bioprinting and tissue-engineering companies such as Organovo (NYSEMKT: ONVO  ) and Modern Meadow. Can it bring back the Dollar Menu, too?

The (un)economics of meat production
I recently spoke with renowned agricultural economist Dr. Thomas Elam, president of FarmEcon, about the forces driving food prices higher. It's a complex issue, but the two largest factors are recent severe droughts and an increased dedication of farmland for ethanol production. Look at how the three major animal feed sources -- corn, dried distillers grains with solubles (DDGS), and soybean meal (SBM) -- have increased in price since the introduction of the Renewable Fuel Standard in 2005, especially in the last two marketing years affected by the 2012 drought.


It doesn't seem so outrageous for McDonald's to can the Dollar Menu after looking at that chart, but the inefficiencies of raising animals for meat production don't end there. The world's 7 billion human inhabitants require an industry of 60 billion domesticated land animals that take up 33% of the planet's ice-free land, consume 8% of our water supply, and emit 18% of human-related greenhouse gases. Here's what goes into making a single quarter-pound hamburger patty:  

•6.7 pounds of animal feed.
•52.8 gallons of water.
•74.5 square feet of land.
•1,036 BTUs (enough to power seven iPads).
•13.4 pounds of CO2 equivalent greenhouse gases.
Multiply that by the nearly 300 million tons of meat produced worldwide each year, and you can see the problem. We can clearly put our land to better use in both economic and environmental terms. And if we want to feed the planet, we may just have to look for a different approach: By 2050 the world will need to produce more than 500 million tons of meat each year. Is there a better way?  

Science to the rescue
Organovo is developing a novel 3-D bioprinting platform with a near-term focus of creating functional human tissues and a long-term focus that's even more ambitious. The company recently announced results from a 40-day study in which its 3-D printed liver tissue demonstrated the ability to produce important proteins and respond to liver toxins -- just as a "natural" liver does. The novel platform has the potential to expedite drug discovery for pharmaceutical companies and save billions of dollars and many lives in the process. In addition, the company could one day grow fully functional human organs and nerves for transplantation, print cancer tumors for research and personalized medicine applications, and create disease models for the most important human organs.

That's just the beginning. If you think of Organovo as a precision tissue engineering company, then the opportunities open up considerably. Any material (product) created by a living organism can be made from cell culture technologies -- we just have to design an optimal system. Those materials do and will include meat, whether you like it or not.

Sound too futuristic? Don't tell that to Andras Forgacs, who co-founded Organovo and Modern Meadow -- a company that creates ultra-sustainable leather and meat with its novel tissue engineering platform. Forgacs believes the platform would come with substantial benefits over traditional livestock production, including:

•99% less land required.
•96% less water consumed.
•96% fewer greenhouse gases emitted.
•45% less energy required.
•No risk of livestock diseases.
•No animals harmed.
Further, meat produced with tissue engineering could be fine-tuned for the most desirable taste, color, texture, nutritional value, and look. I know it sounds crazy, but consider that the meat would be produced from the same exact cells as in, say, farm-raised cattle -- just without the inhumane slaughtering part. The technology could be used to bring food production here on Earth to the 21st century or on spacecraft traveling to Mars and the asteroid belt for the latest mining operation.

Foolish bottom line
If companies such as Organovo and Modern Meadow continue to make progress in developing their platforms, you can bet that one day we'll be able to produce the finest, leanest meats through biotechnology for a fraction of the cost of traditional livestock methods. The world will probably need a giant public awareness campaign to understand the benefits of meat produced from tissue engineering. However, it actually skirts many of the ethical questions surrounding "modern" industrial farming. Knowing the benefits, I'll be first in line for the grand reintroduction of McDonald's Dollar Menu -- featuring lab-grown hamburger patties -- in 2033 (fingers crossed). Who's with me?

MFG
Chali  

Von allen "visionary stocks",die ich je im Depot hatte,ist Organovo die mit abstand visionärste aktie,wie könnte z.b. die Ernähnrung der Weltbevölkerung in zukunft aussehen,komplette menüs,made by Organovo for 1 Dollar ??????  

Sind noch einige andere investiert oder warum ist es hier so ruhig?
Bin auf jeden Fall Long dabei und hoffe dass es so weiter geht.
Das ist hier nämlich die Zukunft!
 

Und freu mich. Eine meiner guten ...  

Ist das ein Lemming,der vor Beginn des absturzes in sicherheit gebracht werden soll ?  

 

Du mußt Deine Gedanken schon als Gedicht vortragen, sonst versteht Dich jetzt aber Keiner  

McDonals hat es abgeschafft,wird es Organovo wieder einführen ?